2-Methoxyestradiol

A metabolite of estradiol that lacks estrogenic activity and inhibits TUBULIN polymerization. It has antineoplastic properties, including inhibition of angiogenesis and induction of APOPTOSIS.

Also Known As:

(17 beta)-2-methoxyestra-1,3,5(10)-triene-3,17-diol; 2-(methyl-11C)Methoxyestradiol; 2-Methoxyestradiol, (17alpha)-isomer; 2-Methoxyestradiol-17 beta; 2-Methoxyoestradiol; Panzem; 2 Methoxyestradiol; 2 Methoxyestradiol 17 beta; 2 Methoxyoestradiol; Estra-1,3,5(10)-triene-3,17-diol, 2-methoxy-, (17beta)-

Networked: 505 relevant articles (34 outcomes, 91 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Kuban-Jankowska, Alicja: 13 articles (07/2022 - 08/2014)
2.	Zhang, Zhenzhong: 10 articles (01/2021 - 01/2010)
3.	Joubert, Annie: 10 articles (02/2015 - 11/2003)
4.	Kumar, Addanki P: 9 articles (10/2021 - 02/2003)
5.	Jackson, Edwin K: 9 articles (12/2019 - 07/2005)
6.	Maran, Avudaiappan: 9 articles (01/2017 - 01/2007)
7.	Shogren, Kristen L: 9 articles (01/2017 - 01/2007)
8.	Yaszemski, Michael J: 9 articles (01/2017 - 01/2007)
9.	Abdel-Naim, Ashraf B: 8 articles (08/2022 - 10/2008)
10.	Salama, Salama A: 8 articles (05/2022 - 12/2006)

Related Diseases

1.	Neoplasms (Cancer) 10/01/2020 - "2-methoxyestradiol (2-ME) has a strong antitumor effect and is effective against numerous types of tumor. " 02/01/2003 - "The exact mechanism of action of 2-methoxyestradiol is still unclear, but it has been shown to be effective in preventing tumor growth in a variety of cell lines. " 01/01/2021 - "The anti-tumor agent 2-methoxyestradiol (2-ME) shows promising results but its efficacy is limited by inadequate pharmacokinetics. " 04/15/2010 - "2-Methoxyestradiol (2ME), an end-metabolite of 17beta-estradiol, is an antiproliferative agent that is currently being tested in clinical trials for cancer treatment. " 02/15/2009 - "Phase I trial of 2-methoxyestradiol NanoCrystal dispersion in advanced solid malignancies."
2.	Prostatic Neoplasms (Prostate Cancer) 07/20/2018 - "Remarkably, treatment of prostate cancer cells with well-studied antitumorigenic agent, 2-methoxyestradiol (2-ME₂), caused significant DNA methylation changes in 3255 genes including COBRA1. " 03/21/2006 - "Modulation of cell-cycle regulatory signaling network by 2-methoxyestradiol in prostate cancer cells is mediated through multiple signal transduction pathways." 10/01/2004 - "Effects of 2-methoxyestradiol on proliferation, apoptosis and PET-tracer uptake in human prostate cancer cell aggregates." 01/01/2004 - "Here we investigated the molecular mechanism by which 2-methoxyestradiol (2-ME) effectively sensitizes a human prostate cancer cell line, PC3, to Fas-mediated apoptosis. " 01/01/2004 - "The molecular mechanism of sensitization to Fas-mediated apoptosis by 2-methoxyestradiol in PC3 prostate cancer cells."
3.	Osteosarcoma (Osteogenic Sarcoma) 10/01/2020 - "Anticancer effects and the mechanism underlying 2-methoxyestradiol in human osteosarcoma in vitro and in vivo." 01/17/2020 - "Herein, we chose osteosarcoma cell lines differed in metastatic potential, metastatic 143B and highly metastatic MG63.2 cells, in order to further investigate the anticancer mechanism of 2-methoxyestradiol. " 04/01/2010 - "2-Methoxyestradiol (2-ME), a naturally occurring metabolite of 17beta-estradiol, induces cell cycle arrest and cell death in human osteosarcoma cells. " 08/01/2008 - "2-Methoxyestradiol (2-ME), a naturally occurring mammalian metabolite of 17beta-Estradiol (E2), induces cell death in osteosarcoma cells. " 01/01/2002 - "Dual effect of 2-methoxyestradiol on cell cycle events in human osteosarcoma 143B cells."
4.	Hypertension (High Blood Pressure) 01/01/2016 - "Effectiveness of 2-methoxyestradiol in alleviating angiogenesis induced by intracranial venous hypertension." 07/01/2005 - "2-Methoxyestradiol had no acute or chronic effects on blood pressure or renal function in normotensive animals or on hypertension in SHR. " 07/01/2014 - "2-Methoxyestradiol deficiency is strongly related to hypertension in early onset severe pre-eclampsia." 12/20/2008 - "2-Methoxyestradiol attenuates hypertension and coronary vascular remodeling in spontaneously hypertensive rats." 01/01/2018 - "Studies have demonstrated the therapeutic potential of estrogen metabolite 2-methoxyestradiol (2ME2) in several cardiovascular disorders, including hypertension. "
5.	Breast Neoplasms (Breast Cancer) 10/01/2023 - "Effect of 2-methoxyestradiol treatment on early- and late-stage breast cancer progression in a mouse model." 06/08/2023 - "Correction: Al-Qahtani et al. Self-Nanoemulsifying Drug Delivery System of 2-Methoxyestradiol Exhibits Enhanced Anti-Proliferative and Pro-Apoptotic Activities in MCF-7 Breast Cancer Cells. " 02/10/2023 - "Radiosensitization of Breast Cancer Cells with a 2-Methoxyestradiol Analogue Affects DNA Damage and Repair Signaling In Vitro." 09/02/2022 - "Self-Nanoemulsifying Drug Delivery System of 2-Methoxyestradiol Exhibits Enhanced Anti-Proliferative and Pro-Apoptotic Activities in MCF-7 Breast Cancer Cells." 01/01/2018 - "A novel non-sulphamoylated 2-methoxyestradiol derivative causes detachment of breast cancer cells by rapid disassembly of focal adhesions."

Related Drugs and Biologics

1.	Estradiol (Delestrogen)
2.	Hormones (Hormone)
3.	Liposomes (Liposome)
4.	Catechol O-Methyltransferase (Methyltransferase, Catechol)
5.	Hydrogels
6.	Reactive Oxygen Species (Oxygen Radicals)
7.	polyethylene glycol-poly(lactide-co-glycolide)
8.	Estrogens (Estrogen)
9.	Antineoplastic Agents (Antineoplastics)
10.	Mercaptoethanol (2 Mercaptoethanol)

Related Therapies and Procedures

1.	Injections
2.	Drug Therapy (Chemotherapy)
3.	Therapeutics
4.	Intravitreal Injections
5.	Hormone Replacement Therapy (Therapy, Hormone Replacement)